Vivatides Therapeutics, a Suzhou, China- and Boston, MA-based biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, raised $54M in Series A funding.
The round was co-led by Qiming Venture Partners, with participation from Highlight Capital, TF Capital, Apricot Capital.
The company intends to further enhance preclinical optimization and IND-enabling studies, expand its R&D and management teams, and continue to accelerate the development of its platform.
Vivatides Therapeutics is a biotechnology company focused on developing new RNA therapeutics, with a focus on extrahepatic delivery (targeting tissues outside of the liver). Its core innovation is a proprietary delivery platform. They use ligand conjugation to guide RNA molecules to specific non-liver tissues. This allows them to treat diseases in areas that were previously difficult for RNA therapies to reach effectively.
Vivatides works with two primary types of RNA-targeting technologies:
- siRNA (Small Interfering RNA): used to “silence” or turn off specific genes that cause disease.
- ASOs (Antisense Oligonucleotides): synthetic strands that can alter gene expression or protein production.
Rather than focusing on rare genetic disorders, the company aims to treat high-prevalence chronic conditions and other major unmet needs, including:
- lMetabolic diseases: leveraging their delivery tech to reach tissues involved in chronic metabolic dysfunction.
- Cardiovascular health: specifically hypertension and hyperlipidemia (high cholesterol).
- Oncology: developing targeted treatments for various cancers.
Don’t just read the news. Own the data. Stop manually tracking deals. Access this round and over 100 others this week—in our structured Master Database (XML) + Weekly Intelligence PDF.
👉 [Access FinSMEs Intelligence Hub]
FinSMEs
13/04/2026